DLH Awarded NIH Cancer Epidemiology and Genetics Contract
July 11 2022 - 8:00AM
DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the
“Company”), a leading provider of innovative health
research services and solutions to federal agencies, today
announced that its subsidiary Social & Scientific Systems, Inc.
has been awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ)
multiple award contract to provide support to the National Cancer
Institute’s (“NCI”) Division of Cancer Epidemiology and Genetics
(“DCEG”). NCI is an institute of the National Institutes of Health
(“NIH”) dedicated to leading, conducting, and supporting cancer
research across the nation with the aim of advancing scientific
knowledge and prolonging human lives.
Through Social & Scientific Systems, Inc, DLH has won a seat
on all Task Areas covered by the ID/IQ, including Field
Preparation, Study Management, and Support Activities; Biospecimen
Activities and Assay Support; Exposure Assessment; and Clinical
Support Activities, and will compete for individual task orders
across the contract. Responsibilities include simultaneously
managing multidisciplinary domestic and international studies with
diverse study designs of varying sizes and complexities. The
multiple-award contract has a five-year base period and a five-year
extension option, and, in aggregate, has a $320 million ceiling for
all awardees. This new ID/IQ contract will replace several previous
NCI contracts, and specific values will be allocated to contractors
as task orders are competed and awarded.
“DLH is thrilled for the opportunity to build upon our
partnership with the renowned researchers of DCEG as we aim to
discover the genetic and environmental determinants of cancer and
find new approaches to preventing the disease,” said Jeanine
Christian, President of DLH’s Public Health & Scientific
Research operating unit. “Our proven experience in simultaneously
executing multiple complex epidemiologic studies, managing sites,
and coordinating with support networks across the globe with rapid
start-up and adaptability enables DLH to jump right into this
potentially life-saving work.”
“This contract vehicle positions DLH to expand our support for
one of the great global public health missions of our time – the
battle against cancer,” said Zach Parker, DLH President & CEO.
“To carry out this vital work, DLH will leverage a deep roster of
highly credentialed staff, a ready-to-tap domestic and
international network for rapid operational and technical support,
and the latest technology and forward-thinking data processes.”
About DLHDLH (NASDAQ:DLHC) delivers improved
health and readiness solutions for federal programs through
research, systems development, and innovative care processes. The
Company’s experts in public health, performance evaluation, and
health operations solve the complex problems faced by civilian and
military customers alike, leveraging digital transformation,
artificial intelligence, advanced analytics, cloud-based
applications, telehealth systems, and more. With over 2,400
employees dedicated to the idea that “Your Mission is Our Passion,”
DLH brings a unique combination of government sector experience,
proven methodology, and unwavering commitment to public health to
improve the lives of millions. For more information, visit
www.DLHcorp.com.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995:This press release may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
relate to future events or DLH`s future financial performance. Any
statements that refer to expectations, projections or other
characterizations of future events or circumstances or that are not
statements of historical fact (including without limitation
statements to the effect that the Company or its management
“believes”, “expects”, “anticipates”, “plans”, “intends” and
similar expressions) should be considered forward looking
statements that involve risks and uncertainties which could cause
actual events or DLH’s actual results to differ materially from
those indicated by the forward-looking statements. Forward-looking
statements in this release include, among others, statements
regarding estimates of future revenues, operating income, earnings
and cash flow. These statements reflect our belief and assumptions
as to future events that may not prove to be accurate. Our actual
results may differ materially from such forward-looking statements
made in this release due to a variety of factors, including: the
outbreak of the novel coronavirus (“COVID-19”), including the
measures to reduce its spread, and its impact on the economy and
demand for our services, are uncertain, cannot be predicted, and
may precipitate or exacerbate other risks and uncertainties; the
risk that we will not realize the anticipated benefits of
acquisitions; the challenges of managing larger and more widespread
operations; contract awards in connection with re-competes for
present business and/or competition for new business; compliance
with new bank financial and other covenants; changes in client
budgetary priorities; government contract procurement (such as bid
and award protests, small business set asides, loss of work due to
organizational conflicts of interest, etc.) and termination risks;
the ability to successfully integrate the operations of
acquisitions; the impact of inflation and higher interest rates;
and other risks described in our SEC filings. For a discussion of
such risks and uncertainties which could cause actual results to
differ from those contained in the forward-looking statements, see
“Risk Factors” in the Company’s periodic reports filed with the
SEC, including our Annual Report on Form 10-K for the fiscal year
ended September 30, 2021, as well as subsequent reports filed
thereafter. The forward-looking statements contained herein are not
historical facts, but rather are based on current expectations,
estimates, assumptions and projections about our industry and
business.Such forward-looking statements are made as of the date
hereof and may become outdated over time. The Company does not
assume any responsibility for updating forward-looking statements,
except as may be required by law.
INVESTOR RELATIONSContact:
Chris WittyPhone: 646-438-9385Email: cwitty@darrowir.com
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Jun 2024 to Jul 2024
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Jul 2023 to Jul 2024